Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma.
Christiansen Gregory A, Nau Cherie B, McLaren Jay W, Johnson Douglas H
AI Summary
Bimatoprost lowers eye pressure in glaucoma patients by significantly increasing aqueous outflow through both pressure-sensitive and pressure-insensitive pathways, without affecting aqueous production.
Abstract
Purpose
To determine the mechanism of ocular hypotensive action of bimatoprost in patients with ocular hypertension or glaucoma.
Design
Double-masked, placebo-controlled, randomized, paired comparison crossover study of the effect of bimatoprost on aqueous humor dynamics.
Participants and controls: Twenty-nine patients with ocular hypertension or glaucoma.
Methods
Bimatoprost and a placebo were administered once a day, in the evening, for 7 days before assessment of aqueous dynamics using tonometry, Schiötz tonography, and fluorophotometry. Intraocular pressure (IOP) response to water drinking was measured.
Main outcome measures
Aqueous humor flow rate, outflow facility, and IOP.
Results
Intraocular pressure was lowered 29% in the morning and 33% at noon by bimatoprost. Aqueous humor flow was unchanged. Tonographic facility of outflow was increased 47% by bimatoprost relative to the placebo. Assuming an extraocular pressure of 8 mmHg and that extraocular pressure is not altered by bimatoprost, the calculated rate of pressure-insensitive outflow was increased 95% by bimatoprost. During the first hour after water drinking, bimatoprost dampened the IOP rise.
Conclusion
As was seen in healthy normal eyes, bimatoprost increased both the pressure-sensitive and the pressure-insensitive outflows of aqueous humor in patients with ocular hypertension or glaucoma. Bimatoprost had no significant effect on aqueous humor formation.
MeSH Terms
Shields Classification
Related Articles5
Aqueous Humor Dynamics Changes and Predictors of IOP Response to Latanoprost in Healthy Subjects.
Clinical TrialProstaglandin F2 alpha-isopropylester eye drops: effects in normal human eyes.
Clinical TrialProstaglandin F2 alpha-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow.
Randomized Controlled TrialEffects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes.
Randomized Controlled TrialUse of topical diclofenac in association with external ocular compression.
Clinical TrialIs this article assigned to the wrong chapter(s)? Let us know.